Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation. Shah Capital had also opposed proposals related to executive compensation. The fund, which owns an about 7.8% stake in Novavax, reiterated that the Sanofi agreement was a "long-awaited step in the right direction".
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.